What's in St Stephens Aids Trust's pipeline?

St Stephens Aids Trust has 13 drugs in our index: 6 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 7 in Phase 1.

Which companies overlap with St Stephens Aids Trust's portfolio?

Top competitors by shared drug class: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Bristol-Myers Squibb, Hospital Universitari Vall d'Hebron Research Institute, Imperial College London, Prism Health North Texas.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/st-stephens-aids-trust.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

St Stephens Aids Trust — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

St Stephens Aids Trust pipeline: 6 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 0 Phase 3 0 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Triumeq	Triumeq	marketed			Other
Darunavir ritonavir	Darunavir ritonavir	marketed	HIV protease inhibitor (boosted)	HIV protease	Infectious Disease / Virology
Tivicay	Tivicay	marketed		Transmembrane protein 97, Integrase, Integrase	Immunology
Darunavir, Ritonavir and Rilpivirine	Darunavir, Ritonavir and Rilpivirine	marketed	Antiretroviral combination (protease inhibitor + NNRTI)	HIV protease, HIV reverse transcriptase	Infectious Disease / Virology
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir	Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir	marketed	Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI)	HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component)	Infectious Disease / Virology
Eviplera®	Eviplera®	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase	Infectious Disease / Virology

Therapeutic area mix

Infectious Disease / Virology · 4
Other · 2
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Hospital Universitari Vall d'Hebron Research Institute · 1 shared drug class
Imperial College London · 1 shared drug class
Prism Health North Texas · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for St Stephens Aids Trust:

Cite this brief

Drug Landscape (2026). St Stephens Aids Trust — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/st-stephens-aids-trust. Accessed 2026-06-10.